PT  - JOURNAL ARTICLE
AU  - Hitt Nichols, Emma
ED  - Cortes, Jorge
TI  - Dasatinib Outcomes Maintained Over 5 Years
DP  - 2014  01
TA  - MD Conference Express
PG  - 19--20
VI  - 14
IP  - 55
4099  - http://mdc.sagepub.com/content/14/55/19.short
4100  - http://mdc.sagepub.com/content/14/55/19.full
AB  - A new analysis from the DASISION trial showed that long-term treatment with dasatinib, compared with imatinib, in patients with treatment-naïve, chronic phase myeloid leukemia improved rates of major molecular response and molecular response, but not overall survival or progression-free survival, in the patients who completed 5 years of follow-up, without new safety signals.